Listen to the news
Kovishield’s study on immune response has been done by CSIR-Institute of Genomics and Integrative Biology (IGIB), Max Super Specialty Hospital and Institute of Endocrinology, Diabetes and Metabolism as well as Academy of Scientific and Innovative Research (ACSIR) Ghaziabad, New Delhi. .
Researchers involved in the study and CSIR-IGIB director Anurag Aggarwal said that a strong immune response is occurring from the covishield. Reactions occur more rapidly in those that are basically seropositive and have higher levels of antibodies.
Seropositivity indicates the presence of a virus in the serum or evidence that the person concerned has previously been exposed to the virus. The Kovishield vaccine is a product of Oxford-AstraZeneca and is being manufactured by the Serum Institute of India, Pune.
Kovishield vs Kovaxin
|This vaccine, prepared in collaboration with the AstraZeneca Company and Oxford University, is made on adenoviruses. It is being produced by the Pune-based Serum Institute of India. This vaccine can be stored at a temperature of 2 to 8 ° C. There is a vaccine for 10 people to be dosed in a vial. It is necessary to take two doses of this vaccine. This vaccine has been reported to be 70 percent effective. During the Phase III trial for this vaccine in India, 1600 people were vaccinated.||
Scientists from the Pune-based National Institute of Virology (NIV) isolate the corona virus and hand it over to the India Biotech company after a Kerala student returned to India after being infected with Wuhan. After this, this vaccine was prepared. This vaccine is up to 81% effective. It can be kept at a temperature from 2 to 8 ° C and it is necessary to take two doses. It is the country’s first indigenous vaccine. Whereas Kovishield is a vaccine produced in the country rather than indigenous. All its tests have been conducted on 27 thousand people in India.